drugset
drugset / Trial / NCT02902601

A Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Participants With Major Depressive Disorder

NCT02902601 ↗

Phase 1 Completed 70 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary purpose of this study is to investigate the safety and tolerability of JNJ 54175446 in participants with Major Depressive Disorder (MDD).

Timeline

Start
2016-10-17
Primary completion
2017-06-02
Completion
2017-06-07

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-54175446 Small molecule 150 mg Oral
Subject JNJ-54175446 Small molecule 600 mg Oral

Indications

major depressive disorder